Skip to main content
Erschienen in: Clinical and Translational Oncology 7/2019

01.12.2018 | Research Article

Cell-free DNA and preoperative chemoradiotherapy for rectal cancer: a systematic review

verfasst von: Anders Kindberg Boysen, Jakob Vasehus Schou, Karen-Lise Garm Spindler

Erschienen in: Clinical and Translational Oncology | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Preoperative chemoradiotherapy is the standard of care for patients with locally advanced rectal cancer, yet valid circulating biomarkers are lacking. We aimed at systematically reviewing the literature of cell-free DNA and locally advanced rectal cancer.

Methods

A systematic literature search was performed. We retrieved papers reporting a correlation between a clinical outcome and cell-free DNA for patients receiving chemoradiotherapy for locally advanced rectal cancer.

Results

We included nine studies of a total of 615 patients. Only single-arm studies were identified, analyzing either the total level of cell-free DNA or tumor-specific DNA. Despite differences in the methodology and outcomes, eight of the nine studies showed a correlation between cell-free DNA and a clinical outcome.

Conclusions

Cell-free DNA might hold prognostic and predictive information for patients with locally advanced rectal cancer receiving preoperative chemoradiotherapy; although, firm conclusions are limited by the heterogeneity in this field.
Literatur
1.
Zurück zum Zitat Giovannucci E, Wu K. Cancers of the colon and rectum. In: Schottenfeld D, Fraumeni J, editors. Cancer. Epidemiology and prevention. 3rd ed. Oxford: Oxford University Press; 2006. Giovannucci E, Wu K. Cancers of the colon and rectum. In: Schottenfeld D, Fraumeni J, editors. Cancer. Epidemiology and prevention. 3rd ed. Oxford: Oxford University Press; 2006.
2.
Zurück zum Zitat Glynne-Jones R, Wyrwicz L, Tiret E, et al. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv22–40.CrossRefPubMed Glynne-Jones R, Wyrwicz L, Tiret E, et al. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv22–40.CrossRefPubMed
3.
Zurück zum Zitat Kapiteijn E, Marijnen C, Nagtegaal I, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638–46.CrossRefPubMed Kapiteijn E, Marijnen C, Nagtegaal I, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638–46.CrossRefPubMed
4.
Zurück zum Zitat Ngan S, Burmeister B, Fisher R, et al. Randomized trial of short course radiotherapy versus long course chemoradiation comparing rates of local recurrence in patients with T4 rectal cancer: Trans Tasman Radiation Oncology Group Trial 01.04. J Clin Oncol. 2012;30:3827–33.CrossRefPubMed Ngan S, Burmeister B, Fisher R, et al. Randomized trial of short course radiotherapy versus long course chemoradiation comparing rates of local recurrence in patients with T4 rectal cancer: Trans Tasman Radiation Oncology Group Trial 01.04. J Clin Oncol. 2012;30:3827–33.CrossRefPubMed
5.
Zurück zum Zitat Leichman C, McDonough S, Smalley S, et al. Cetuximab combined with induction oxaliplatin and capecitabine, followed by neoadjuvant chemoradiation for locally advanced rectal cancer: SWOG 0713. Clin Colorectal Cancer. 2017;17:e121–5.CrossRefPubMedPubMedCentral Leichman C, McDonough S, Smalley S, et al. Cetuximab combined with induction oxaliplatin and capecitabine, followed by neoadjuvant chemoradiation for locally advanced rectal cancer: SWOG 0713. Clin Colorectal Cancer. 2017;17:e121–5.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Appelt A, Pløen J, Harling H, et al. High dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. Lancet Oncol. 2015;16:919–27.CrossRefPubMed Appelt A, Pløen J, Harling H, et al. High dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. Lancet Oncol. 2015;16:919–27.CrossRefPubMed
7.
Zurück zum Zitat Brown G, et al. Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathological comparison. Radiology. 2003;227(2):371–7.CrossRefPubMed Brown G, et al. Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathological comparison. Radiology. 2003;227(2):371–7.CrossRefPubMed
8.
Zurück zum Zitat Dayde D, Tanaka I, Tai M, et al. Predictive and Prognostic molecular biomarkers for response to neoadjuvant chemoradiation in rectal cancer. Int J Mol Sci. 2017;18:573.CrossRefPubMedCentral Dayde D, Tanaka I, Tai M, et al. Predictive and Prognostic molecular biomarkers for response to neoadjuvant chemoradiation in rectal cancer. Int J Mol Sci. 2017;18:573.CrossRefPubMedCentral
9.
Zurück zum Zitat Mandel P, Metasis P. Les acides nucleiques du plasma sanguis chez l’homme. CR Seances Soc Biol Fil. 1948;142:241–3. Mandel P, Metasis P. Les acides nucleiques du plasma sanguis chez l’homme. CR Seances Soc Biol Fil. 1948;142:241–3.
10.
Zurück zum Zitat Leon SA, Shapiro B, Sklaroff DM, et al. Free DNA in the serum of patients and the effect of therapy. Cancer Res. 1977;37:646–50.PubMed Leon SA, Shapiro B, Sklaroff DM, et al. Free DNA in the serum of patients and the effect of therapy. Cancer Res. 1977;37:646–50.PubMed
11.
Zurück zum Zitat Spindler KL, Boysen AK, Pallisgaard N, et al. Cell free DNA in metastatic colorectal cancer—a systematic review and meta analysis. Oncologist. 2017;22(9):1049–55.CrossRefPubMedPubMedCentral Spindler KL, Boysen AK, Pallisgaard N, et al. Cell free DNA in metastatic colorectal cancer—a systematic review and meta analysis. Oncologist. 2017;22(9):1049–55.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, Altman DG, Prisma Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;151(4):264–9. Moher D, Liberati A, Tetzlaff J, Altman DG, Prisma Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;151(4):264–9.
13.
Zurück zum Zitat Whitting PF, Rutjes A, Westwood M, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529–36.CrossRef Whitting PF, Rutjes A, Westwood M, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529–36.CrossRef
14.
Zurück zum Zitat Zitt M, Muller H, Rochel M, et al. Circulating cell free DNA in plasma of locally advanced rectal cancer patients undergoing preoperative chemoradiation: a potential diagnostic tool for therapy monitoring. Dis Markers. 2008;25(3):159–65.CrossRefPubMedPubMedCentral Zitt M, Muller H, Rochel M, et al. Circulating cell free DNA in plasma of locally advanced rectal cancer patients undergoing preoperative chemoradiation: a potential diagnostic tool for therapy monitoring. Dis Markers. 2008;25(3):159–65.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Agostine M, Pucciarelli S, Vittoria M, et al. Circulating cell free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiation. Ann Surg Oncol. 2011;18:2461–8.CrossRef Agostine M, Pucciarelli S, Vittoria M, et al. Circulating cell free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiation. Ann Surg Oncol. 2011;18:2461–8.CrossRef
16.
Zurück zum Zitat Sun W, Sun Y, Zhu M, et al. The role of plasma cell free DNA detection in predicting preoperative chemoradiotherapy response in rectal cancer patients. Oncol Rep. 2014;31:1466–72.CrossRefPubMed Sun W, Sun Y, Zhu M, et al. The role of plasma cell free DNA detection in predicting preoperative chemoradiotherapy response in rectal cancer patients. Oncol Rep. 2014;31:1466–72.CrossRefPubMed
17.
Zurück zum Zitat Carpinetti P, Donnard E, Bettoni F, et al. The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation. Oncotarget. 2015;6(35):38360–71.CrossRefPubMedPubMedCentral Carpinetti P, Donnard E, Bettoni F, et al. The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation. Oncotarget. 2015;6(35):38360–71.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Boysen AK, Wettergren Y, Sørensen BS, et al. Cell-free DNA levels and correlation to stage and outcome following treatment of locally advanced rectal cancer. Tumor Biol. 2017;39(11):1–6.CrossRef Boysen AK, Wettergren Y, Sørensen BS, et al. Cell-free DNA levels and correlation to stage and outcome following treatment of locally advanced rectal cancer. Tumor Biol. 2017;39(11):1–6.CrossRef
19.
Zurück zum Zitat Schou JV, Larsen FO, Sørensen BS, et al. Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancer. Ann Oncol. 2018;0:1–6. Schou JV, Larsen FO, Sørensen BS, et al. Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancer. Ann Oncol. 2018;0:1–6.
20.
Zurück zum Zitat Sclafani F, Chau I, Cunningham D, et al. KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer. Sci Rep. 2018;8:1445.CrossRefPubMedPubMedCentral Sclafani F, Chau I, Cunningham D, et al. KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer. Sci Rep. 2018;8:1445.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Tie J, Cohen J, Wang Y, et al. Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. Gut. 2018;0:1–9. Tie J, Cohen J, Wang Y, et al. Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. Gut. 2018;0:1–9.
22.
Zurück zum Zitat Li M, Xiao W, Zhao G, et al. Predictive value of circulating tumor DNA in locally advanced rectal cancer patients receiving neoadjuvant radiochemotherapy. J Clin Oncol. 2017;35:n15_supplement. Li M, Xiao W, Zhao G, et al. Predictive value of circulating tumor DNA in locally advanced rectal cancer patients receiving neoadjuvant radiochemotherapy. J Clin Oncol. 2017;35:n15_supplement.
23.
Zurück zum Zitat Ryan JE, Warrier SK, Lynch AC, et al. Assessing pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review. Colorectal Dis. 2015;17:849–61.CrossRefPubMed Ryan JE, Warrier SK, Lynch AC, et al. Assessing pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review. Colorectal Dis. 2015;17:849–61.CrossRefPubMed
24.
Zurück zum Zitat Glynne-Jones R, Wyrwicz L, Tiret E, et al. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28((Supplement 4)):iv22–40.CrossRefPubMed Glynne-Jones R, Wyrwicz L, Tiret E, et al. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28((Supplement 4)):iv22–40.CrossRefPubMed
25.
Zurück zum Zitat Negri FV, Campanini N, Camisa R, et al. Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. Br J Cancer. 2008;98:143–7.CrossRefPubMed Negri FV, Campanini N, Camisa R, et al. Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. Br J Cancer. 2008;98:143–7.CrossRefPubMed
26.
Zurück zum Zitat Sturm I, Rau B, Schlag PM, et al. Genetic dissection of apoptosis and cell cycle control in response of colorectal cancer treated with preoperative radiochemotherapy. BMC Cancer. 2006;6:124.CrossRefPubMedPubMedCentral Sturm I, Rau B, Schlag PM, et al. Genetic dissection of apoptosis and cell cycle control in response of colorectal cancer treated with preoperative radiochemotherapy. BMC Cancer. 2006;6:124.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Spindler KL, Nielsen JN, Lindebjerg J, et al. Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region. Int J Radiat Oncol Biol Phys. 2006;66:500–4.CrossRefPubMed Spindler KL, Nielsen JN, Lindebjerg J, et al. Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region. Int J Radiat Oncol Biol Phys. 2006;66:500–4.CrossRefPubMed
28.
Zurück zum Zitat Hur H, Kim NK, Min B, et al. Can a biomarker-based scoring system predict pathologic complete response after preoperative chemoradiothreapy for rectal cancer? Dis Colon Rectum. 2014;57:5.CrossRef Hur H, Kim NK, Min B, et al. Can a biomarker-based scoring system predict pathologic complete response after preoperative chemoradiothreapy for rectal cancer? Dis Colon Rectum. 2014;57:5.CrossRef
29.
Zurück zum Zitat Probst C, Beccera A, Acuina C, et al. Watch and wait?—elevated pretreatment CEA Is associated with decreased pathological complete response in rectal cancer. J Gastrointest Surg. 2016;20:43–52.CrossRefPubMed Probst C, Beccera A, Acuina C, et al. Watch and wait?—elevated pretreatment CEA Is associated with decreased pathological complete response in rectal cancer. J Gastrointest Surg. 2016;20:43–52.CrossRefPubMed
30.
Zurück zum Zitat Spindler KL. Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer. Acta Oncol. 2017;56(1):7–16.CrossRefPubMed Spindler KL. Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer. Acta Oncol. 2017;56(1):7–16.CrossRefPubMed
31.
Zurück zum Zitat Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486:532–6.CrossRefPubMedPubMedCentral Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486:532–6.CrossRefPubMedPubMedCentral
Metadaten
Titel
Cell-free DNA and preoperative chemoradiotherapy for rectal cancer: a systematic review
verfasst von
Anders Kindberg Boysen
Jakob Vasehus Schou
Karen-Lise Garm Spindler
Publikationsdatum
01.12.2018
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 7/2019
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-018-1997-y

Weitere Artikel der Ausgabe 7/2019

Clinical and Translational Oncology 7/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.